LFG
AKBA icon

Larson Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Larson Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$976 Hold
856
– – ﹤0.01% 3327
2026
Q1 		$1.19K Buy
856
+82
+11% +$113 ﹤0.01% 3099
2025
Q4 		$1.25K Buy
+774
New +$1.62K ﹤0.01% 2900

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Larson Financial Group's AKBA Position: Q2 2026 in Review

Larson Financial Group held its Akebia Therapeutics (AKBA) position steady in Q2 2026 at 856 shares worth $976. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

Larson Financial Group first reported a position in AKBA in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.25K in Q4 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Larson Financial Group held 856 shares of Akebia Therapeutics worth $976 as of Q2 2026.
  • Larson Financial Group left its Akebia Therapeutics share count unchanged in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3327 holding.
  • Larson Financial Group first reported a position in Akebia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Larson Financial Group's Akebia Therapeutics position peaked at $1.25K in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.